BCL2L11 and non-small cell lung carcinoma: In cells with activating EGFR somatic mutations, BIM’s pro-apoptotic effects are synergistic with the loss of survivin, whose downregulation enhances gefitinib-induced apoptotic death in TKI-sensitive NSCLC cells [117].